A synthetic tetrapeptide with longevity claims resting almost entirely on work from a single Russian institute. No independent replication and no modern registered trials.
Epithalon is a four-amino-acid peptide designed as a simplified copy of a pineal gland extract. The claims around it centre on telomerase, the enzyme that maintains the protective caps on chromosomes. Published work from one institute reports telomerase activation in cell culture and extended lifespan in rodents. That work has not been independently replicated by other groups, which is the single most important thing to know about this compound.
Epithalon is the tetrapeptide Ala-Glu-Asp-Gly (AEDG), derived by sequence reduction from Epithalamin, a bovine pineal gland extract. The proposed mechanism is epigenetic: the peptide is reported to enter the nucleus and bind specific DNA sequences in promoter regions, modulating transcription of genes including TERT. Reported effects include induction of telomerase activity and telomere elongation in cultured human fibroblasts, normalization of melatonin rhythm in aged animals, and restoration of thymic architecture. Independent structural or binding data confirming direct DNA interaction are not available in the mainstream literature, and the reported effects have not been reproduced outside the originating research programme.
Research areas
Community-specified data
Source note: 10mg/day for 10 days = 100mg total. Repeat only 2x/year
Not medical guidance. These third-party figures have not been independently verified, clinically reviewed, or endorsed by DB Peptide. They may be inaccurate or unsafe and should not replace product labelling or advice from a qualified clinician.
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| 10 mg intramuscularly daily for 10 days, repeated in annual courses, in the published geroprotective studiesReported from the originating institute's protocols. Not validated by any independent trial. | Khavinson et al., Bulletin of Experimental Biology and Medicine |
| Nanomolar concentrations in cultured human fibroblast telomerase experimentsIn vitro concentration, not a dose. | Khavinson et al., Bulletin of Experimental Biology and Medicine 2003 |
Observational and controlled studies published by the St. Petersburg Institute of Bioregulation and Gerontology. No registered trials on ClinicalTrials.gov and no independent replication.
Rodent studies reported increased mean lifespan and reduced spontaneous tumour incidence in some models, with contradictory findings in others.
A long-running observational cohort of elderly patients reported reduced mortality over follow-up. Published only within the originating institute's programme, without independent verification.
No study from an unaffiliated research group has reproduced the telomerase or lifespan findings.
Grade F is reserved for compounds where well-conducted human evidence shows no effect or net harm. Epithalon has published preclinical and observational human data reporting positive findings — the problem is that it originates almost entirely from one institute and has never been independently replicated. That is a grade D profile: a real but unverified evidence base.
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →